JP2015516801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516801A5 JP2015516801A5 JP2014561381A JP2014561381A JP2015516801A5 JP 2015516801 A5 JP2015516801 A5 JP 2015516801A5 JP 2014561381 A JP2014561381 A JP 2014561381A JP 2014561381 A JP2014561381 A JP 2014561381A JP 2015516801 A5 JP2015516801 A5 JP 2015516801A5
- Authority
- JP
- Japan
- Prior art keywords
- binding
- seq
- cancer
- amino acid
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12159938 | 2012-03-16 | ||
| EP12159938.5 | 2012-03-16 | ||
| PCT/EP2013/054768 WO2013135588A1 (en) | 2012-03-16 | 2013-03-08 | Novel binding molecules with antitumoral activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516801A JP2015516801A (ja) | 2015-06-18 |
| JP2015516801A5 true JP2015516801A5 (https=) | 2016-04-21 |
| JP6325463B2 JP6325463B2 (ja) | 2018-05-16 |
Family
ID=47844323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561381A Expired - Fee Related JP6325463B2 (ja) | 2012-03-16 | 2013-03-08 | 抗腫瘍活性を有する新規結合分子 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9593314B2 (https=) |
| EP (1) | EP2825197B1 (https=) |
| JP (1) | JP6325463B2 (https=) |
| KR (1) | KR20140135251A (https=) |
| CN (1) | CN104284675B (https=) |
| AU (1) | AU2013231488B2 (https=) |
| BR (1) | BR112014022932A2 (https=) |
| CA (1) | CA2865597A1 (https=) |
| MX (1) | MX354717B (https=) |
| NZ (1) | NZ629283A (https=) |
| RU (1) | RU2627185C1 (https=) |
| WO (1) | WO2013135588A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013110030A2 (en) | 2012-01-19 | 2013-07-25 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
| EP2752426A1 (en) | 2013-01-03 | 2014-07-09 | Covagen AG | Human serum albumin binding compounds and fusion proteins thereof |
| AU2014357292B2 (en) | 2013-11-27 | 2020-06-25 | Zymeworks Bc Inc. | Bispecific antigen-binding constructs targeting HER2 |
| WO2015109012A1 (en) * | 2014-01-14 | 2015-07-23 | Integrated Biotherapeutics, Inc. | Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins |
| JP2017507950A (ja) | 2014-02-27 | 2017-03-23 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法 |
| CA2942546C (en) * | 2014-03-17 | 2022-11-22 | Mitsubishi Tanabe Pharma Corporation | Antibody-fynomer conjugates |
| JP6523337B2 (ja) | 2014-05-05 | 2019-05-29 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物 |
| EP3140291A4 (en) | 2014-05-05 | 2018-01-10 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| CA2954279C (en) | 2014-07-07 | 2023-11-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| WO2016082044A1 (en) | 2014-11-27 | 2016-06-02 | Zymeworks Inc. | Methods of using bispecific antigen-binding constructs targeting her2 |
| US10421751B2 (en) | 2015-05-05 | 2019-09-24 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| AU2016276947A1 (en) | 2015-06-11 | 2017-12-14 | Lycera Corporation | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| FI126633B (en) | 2015-07-10 | 2017-03-15 | Next Biomed Therapies Oy | Method for the preparation of a library of derivatives of the SH3 domain of recombinant nephrocystin (NPHP1) |
| US11253580B2 (en) | 2016-01-07 | 2022-02-22 | Duke University | Cancer vaccines and methods of delivery |
| US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
| EP4015532A1 (en) | 2016-11-21 | 2022-06-22 | cureab GmbH | Anti-gp73 antibodies and immunoconjugates |
| US10722589B2 (en) * | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
| US20190153096A1 (en) | 2017-10-02 | 2019-05-23 | Covagen Ag | Cd3/cd33 bispecific binding molecules |
| US20190100587A1 (en) | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| AU2019205090A1 (en) | 2018-01-05 | 2020-08-06 | Ac Immune Sa | Misfolded TDP-43 binding molecules |
| JP7350756B2 (ja) | 2018-02-14 | 2023-09-26 | アバ セラピューティクス アーゲー | 抗ヒトｐｄ－ｌ２抗体 |
| RU2018111298A (ru) * | 2018-03-29 | 2019-10-01 | Закрытое Акционерное Общество "Биокад" | Биспецифическое антитело, которое специфично связывается с IV и II cубдоменами внеклеточного домена HER2 человека |
| JP7689373B2 (ja) | 2019-04-18 | 2025-06-06 | エイシー イミューン ソシエテ アノニム | 治療及び診断のための新規分子 |
| AU2020278907A1 (en) | 2019-05-23 | 2022-01-20 | Ac Immune Sa | Anti-TDP-43 binding molecules and uses thereof |
| JP7691701B2 (ja) | 2019-06-18 | 2025-06-12 | マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | 金属錯体試薬を介するＨｉｓタグ付タンパク質などの標的分子への標識および／または担体の部位特異的、速度論的に不活性なコンジュゲーション |
| WO2021099484A1 (en) | 2019-11-20 | 2021-05-27 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Archaeal peptide recombinase – a novel peptide ligating enzyme |
| CA3164226A1 (en) | 2019-12-11 | 2021-06-17 | Cilag Gmbh International | Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof |
| WO2022029306A1 (en) | 2020-08-07 | 2022-02-10 | F. Hoffmann-La Roche Ag | Method for producing protein compositions |
| TW202221026A (zh) | 2020-08-14 | 2022-06-01 | 瑞士商Ａｃ 免疫有限公司 | 人源化抗ｔｄｐ－４３結合分子及其用途 |
| WO2022043517A2 (en) | 2020-08-27 | 2022-03-03 | Cureab Gmbh | Anti-golph2 antibodies for macrophage and dendritic cell differentiation |
| EP4229082A1 (en) | 2020-10-16 | 2023-08-23 | AC Immune SA | Antibodies binding to alpha-synuclein for therapy and diagnosis |
| WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| AU2022390134A1 (en) | 2021-11-16 | 2024-05-16 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CA3243689A1 (en) | 2022-02-16 | 2023-08-24 | Ac Immune Sa | Humanized Anti-TDP-43 Bonding Molecules and Their Uses |
| US20260043816A1 (en) | 2022-04-08 | 2026-02-12 | Ac Immune Sa | Anti-TDP-43 Binding Molecules |
| WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| EP4676596A1 (en) | 2023-03-08 | 2026-01-14 | AC Immune SA | Anti-tdp-43 binding molecules and uses thereof |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025221728A2 (en) | 2024-04-15 | 2025-10-23 | Janssen Biotech, Inc. | Ltbr binding molecules and uses thereof |
| WO2026013218A1 (en) | 2024-07-10 | 2026-01-15 | Ac Immune Sa | Anti-tdp-43 vectors, binding molecules and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184205B1 (en) | 1994-07-22 | 2001-02-06 | University Of North Carolina At Chapel Hill | GRB2 SH3 binding peptides and methods of isolating and using same |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| GT200500155A (es) * | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
| DK1771482T3 (da) * | 2004-07-22 | 2014-10-20 | Genentech Inc | HER2-antistofsammensætning |
| AU2005282720B2 (en) | 2004-09-02 | 2011-08-04 | Genentech, Inc. | Anti-FC-gamma RIIB receptor antibody and uses therefor |
| EP1892248A1 (en) * | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| US9513296B2 (en) | 2006-08-21 | 2016-12-06 | Eidgenoessische Technische Hochschule Zurich | Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| NZ584514A (en) | 2007-10-19 | 2012-07-27 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| WO2011020033A2 (en) | 2009-08-13 | 2011-02-17 | Massachusetts Institute Of Technology | Engineered proteins including mutant fibronectin domains |
| MX2012002428A (es) * | 2009-08-27 | 2012-09-12 | Covagen Ag | Compuestos de union il-17 y usos medicos de los mismos. |
| CN102770456B (zh) | 2009-12-04 | 2018-04-06 | 弗·哈夫曼-拉罗切有限公司 | 多特异性抗体、抗体类似物、组合物和方法 |
| RU2553333C2 (ru) * | 2009-12-14 | 2015-06-10 | Сцил Протеинс Гмбх | Способ идентификации гетеромультимерных модифицированных убиквитиновых белков со способностью связываться с лигандами |
| EP2576621B1 (en) * | 2010-05-27 | 2019-04-10 | Genmab A/S | Monoclonal antibodies against her2 |
| WO2012009705A1 (en) * | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
-
2013
- 2013-03-08 JP JP2014561381A patent/JP6325463B2/ja not_active Expired - Fee Related
- 2013-03-08 RU RU2014141598A patent/RU2627185C1/ru not_active IP Right Cessation
- 2013-03-08 AU AU2013231488A patent/AU2013231488B2/en not_active Ceased
- 2013-03-08 CA CA2865597A patent/CA2865597A1/en not_active Abandoned
- 2013-03-08 CN CN201380014237.9A patent/CN104284675B/zh not_active Expired - Fee Related
- 2013-03-08 EP EP13708424.0A patent/EP2825197B1/en not_active Not-in-force
- 2013-03-08 US US14/385,729 patent/US9593314B2/en not_active Expired - Fee Related
- 2013-03-08 NZ NZ629283A patent/NZ629283A/en not_active IP Right Cessation
- 2013-03-08 BR BR112014022932A patent/BR112014022932A2/pt not_active Application Discontinuation
- 2013-03-08 MX MX2014011066A patent/MX354717B/es active IP Right Grant
- 2013-03-08 WO PCT/EP2013/054768 patent/WO2013135588A1/en not_active Ceased
- 2013-03-08 KR KR1020147029084A patent/KR20140135251A/ko not_active Ceased
-
2017
- 2017-03-09 US US15/454,769 patent/US20170281768A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015516801A5 (https=) | ||
| JP2016516789A5 (https=) | ||
| NZ708182A (en) | Bispecific t cell activating antigen binding molecules | |
| JP2013166763A5 (https=) | ||
| FI3348571T3 (fi) | Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini | |
| MX354717B (es) | Moleculas de union novedosas con actividad antitumoral. | |
| JP2020506971A5 (https=) | ||
| IL256871B2 (en) | Constructs for bispecific antibodies binding dll3 and cd3 and uses thereof | |
| JP2017140051A5 (https=) | ||
| RU2022102446A (ru) | Биспецифические связывающие белки и пути их применения | |
| JP2014088414A5 (https=) | ||
| HRP20192347T1 (hr) | Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora | |
| RU2017108203A (ru) | Слитые белки sirp-альфа с иммуноглобулином | |
| JP2013509879A5 (https=) | ||
| JP2013500715A5 (https=) | ||
| JP2015119705A5 (https=) | ||
| RU2014109557A (ru) | Антитела, не содержащие fc-фрагмента, включающие два fab-фрагмента, и способы их применения | |
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| JP2011510632A5 (https=) | ||
| HRP20211788T1 (hr) | Postupak i pripravci za poboljšanje anti-tumorskog efektorskog funkcioniranja t stanica | |
| EA201891641A1 (ru) | Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста | |
| RU2012153241A (ru) | Антитела к fgfr2 | |
| NZ622452A (en) | Lsr antibodies, and uses thereof for treatment of cancer | |
| TN2011000524A1 (en) | Antibodies specific to cadherin -17 | |
| RS53872B2 (sr) | Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana |